Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 643Other hematologic neoplasm 459Breast 338Plasma cell 184Myeloid 132Sarcoma 110CNS 87Dermatologic 85Classical hematology 54Gynecologic 50Gastrointestinal 46Genitourinary 43Thoracic 35Other solid neoplasm 24Head & Neck 13Tumor-Agnostic 9Other neoplasm 4Other 2Endocrine 2NET 1

Conditions

Wilms Tumor 1Sarcoma 1Retinoblastoma 1Neuroendocrine Tumors 1Neuroblastoma 1Kidney Neoplasms 1Adrenocortical Carcinoma 1

Interventions

Everolimus 32Octreotide 15Cisplatin 14pasireotide 13Sunitinib 13Temozolomide 11pembrolizumab 10Etoposide 10Doxorubicin 10lanreotide 9Magnetic Resonance Spectroscopy 9Bevacizumab 9lutetium Lu 177 dotatate 8gallium Ga 68 dotatate 8Sorafenib 8Paclitaxel 83-Iodobenzylguanidine 8lenvatinib 7pazopanib 6Radiotherapy 6Positron Emission Tomography Computed Tomography 6surufatinib 5cabozantinib 5avelumab 5Thyrotropin Alfa 5Surgical Procedures, Operative 5Radiosurgery 5Nivolumab 5Mitotane 5Irinotecan 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Cyclophosphamide × Endocrine × Clear all
NCT00605566 2019-02-19

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

University Health Network, Toronto

Phase 2 Completed
22 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

NCT01048892 2014-01-30

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Children's Oncology Group

Phase 1 Completed
22 enrolled
CNSEndocrineGenitourinaryOther solid neoplasmSarcoma

Kidney Neoplasms, Wilms Tumor, Neuroblastoma, Retinoblastoma, Sarcoma, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡